The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity.

ABSTRACT: Doxorubicin is a commonly used chemotherapeutic agent for the treatment of a range of cancers, but despite its success in improving cancer survival rates, doxorubicin is cardiotoxic and can lead to congestive heart failure. Therapeutic options for this patient group are limited to standard heart failure medications with the only drug specific for doxorubicin cardiotoxicity to reach FDA approval being dexrazoxane, an iron-chelating agent targeting oxidative stress. However, dexrazoxane has failed to live up to its expectations from preclinical studies while also bringing up concerns about its safety. Despite decades of research, the molecular mechanisms of doxorubicin cardiotoxicity are still poorly understood and oxidative stress is no longer considered to be the sole evil. Mitochondrial i

SUBMITTER: Timm KN 

PROVIDER: S-EPMC7125062 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature